

From Immunology and Autoimmunity to Haematology and back

Virtual | 22-23 May 2026

PRELIMINARY PROGRAMME



Friday, 22 May 2026

(All timing in CEST)

14:00 – 14:15 Meeting Opening

Tobias Alexander (DE), Maria Ester Bernardo and Krzysztof Kałwak

14:15 – 15:30 Session 1: Indications and recommendations

Chairs: Tobias Alexander (DE) and Krzysztof Kałwak (PL)

14:15-14:35

Indications for autologous HCT in Autoimmune Diseases

Elisa Roldan (UK)

14:35-14:55

CAR-T for Autoimmune Diseases. Clinical practise recommendations from EBMT

Raffaella Greco (IT)

14:55-15:15

Indications for HCT in paediatric autoimmune disorders

Juliana Silva (UK)

15:15-15:30

Session Discussion

15:45 – 16:35 Session 2: CAR-T for autoimmune diseases, where do we stand?

Chairs: Tobias Alexander (DE) and Krzysztof Kałwak (PL)

15:45-16:10

CART-T in adult autoimmune diseases

16:10-16:35

CART-T in paediatric autoimmune diseases

Marco Becilli (IT)

16:45 – 18:00 Session 3: Gene therapy

Chairs: Maria Ester Bernardo (IT) and Claire Booth (UK)

16:45-17:05

HSC-GT for Inborn Errors of Immunity

Claire Booth (UK)

17:05-17:25

HSC-GT for Inborn Error of Metabolism

Maria Ester Bernardo (IT)

17:25-17:45

Future perspectives of GT strategies, regulatory aspects and accessibility

Alessandro Aiuti (IT)

17:45-18:00

Session Discussion

From Immunology and Autoimmunity to Haematology and back

Virtual | 22-23 May 2026

PRELIMINARY PROGRAMME



Saturday, 23 May 2026

(All timing in CEST)

09:00 – 10:15 **Session 4: Rheumatic and neurological autoimmune diseases**

Chairs: Tobias Alexander (DE) and Elisa Roldan (UK)

09:00-09:20 CAR-T for Multiple Sclerosis
09:20-09:40 Tailored AHSCT Therapy for Systemic Sclerosis
09:40-10:00 T-cell engagers for systemic sclerosis
10:00-10:15 Session Discussion

Johanna Richter (DE)
Doron Rimar (IL)

10:30 – 11:45 **Session 5: Conditioning**

Chairs: Fulvio Porta (IT) and Nameer Al-Saadawi (AE)

10:00-10:20 Optimizing serotherapy before HCT
10:20-10:40 Low dose radiotherapy as part of conditioning therapy
10:40-11:20 Pros and cons: busulfan versus treosulfan in non-malignant disorders
11:20-11:45 Session Discussion

Arjan Lankester (NL)
Fulvio Porta (IT)
T: Krzysztof Kałwak (PL)
B: Arjan Lankester (NL)

12:00 – 13:00 **Session 6: Best Abstracts**

Chairs: Claire Horgan (UK) & Rosamaria Nitti (IT)

12:00-12:10 Best Abstract 1
12:10-12:20 Best Abstract 2
12:20-12:30 Best Abstract 3
12:30-12:40 Best Abstract 4
12:40-12:50 Best Abstract 5
12:50-13:00 Best Abstract 6

13:30 – 14:45 **Session 7: Complications**

Chairs: Krzysztof Kałwak (PL) and Giovanna Lucchini (IT)

13:30-13:50 Secondary AD after allo-transplantation haematologic malignancies
13:50-14:10 Fertility preservation in CAR-T cell therapy
14:10-14:30 HLH after CAR-T
14:30-14:45 Session Discussion

Giorgio Orofino (IT)
Giovanna Lucchini (IT)

15:00 – 16:15 **Session 8: Expanding the horizon of HCT**

Chairs: Raffaella Greco (IT)

15:00-15:20 HCT's evolution from classical PIDs to PIRDs
15:20-15:40 Primary immune deficiency and cancer: chemotherapy and HCT
15:40-16:00 Bringing HCT to children in lower/middle income countries
16:00-16:15 Session Discussion

Andrew Gennery (UK)
Kirill Kirgizov (RU)
Lawrence Faulkner (IT)

16:15 – 16:30 **Meeting Closing Remarks**

Tobias Alexander (DE), Maria Ester Bernardo and Krzysztof Kałwak

For further information, please contact education.events@ebmt.org